#152934

Anti-deltaEGFR [DH8.3] mAb

Cat. #152934

Anti-deltaEGFR [DH8.3] mAb

Cat. #: 152934

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-5 days

Target: Epidermal growth factor receptor, truncated EGF receptor (RGFR typeIII/EGFRvIII/deltaEGFR). Recognises an EGFR with truncated extracellular domain, present on human tumours.

Class: Monoclonal

Application: ELISA ; FACS ; IHC ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Bill Gullick

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Primary Citation: Hills et al. 1995. Int J Cancer. 63(4):537-43. PMID: 7591264.

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-deltaEGFR [DH8.3] mAb
  • Alternate name: EGFRvIII, Avian erythroblastic leukemia viral (v erb b) oncogene homolog, Cell growth inhibiting protein 4, Cell proliferation inducing protein 61, EGF R, EGFR, Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog), Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian), Epidermal growth factor receptor, erb-b2 receptor tyrosine kinase 1, ERBB, ERBB1, Errp, HER1, mENA, NISBD2, Oncogen ERBB, PIG61, Proto-onc...
  • Clone: DH8.3
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Cell signalling pathway: EGFR
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; FACS ; IHC ; IP ; WB
  • Description: Monoclonal antibody directed against deltaEGFR, a mutated form of EGFR, typically found in brain tumours, also known as EGFRvIII. This antibody has use within radiolabelled tumour imaging and potentially therapeutic targeting against deltaEGFR tumours.

    Background and Research Application

    Epidermal growth factor (EGFR) has attracted considerable attention as a target for cancer therapy. Wild-type EGFR is amplified in a number of cancers, and several mutant forms of the EGFR cod...
  • Immunogen: Synthetic peptide corresponding to the junctional region of the truncated receptor LEEKKGNYVVTDHC,conjugated to keyhole limpet haemcyanin.
  • Immunogen uniprot id: P00533
  • Isotype: IgG1 kappa
  • Myeloma used: NS0

Target Details

  • Target: Epidermal growth factor receptor, truncated EGF receptor (RGFR typeIII/EGFRvIII/deltaEGFR). Recognises an EGFR with truncated extracellular domain, present on human tumours.
  • Target background: Monoclonal antibody directed against deltaEGFR, a mutated form of EGFR, typically found in brain tumours, also known as EGFRvIII. This antibody has use within radiolabelled tumour imaging and potentially therapeutic targeting against deltaEGFR tumours.

    Background and Research Application

    Epidermal growth factor (EGFR) has attracted considerable attention as a target for cancer therapy. Wild-type EGFR is amplified in a number of cancers, and several mutant forms of the EGFR cod...

Applications

  • Application: ELISA ; FACS ; IHC ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4° C

References

  • Genßler et al. 2016. Oncoimmunology. 5(4):e1119354. PMID: 27141401.
  • Feng et al. 2014. J Clin Invest. 124(9):3741-56. PMID: 25061874.
  • Feng et al. 2012. Proc Natl Acad Sci U S A. 109(8):3018-23. PMID: 22323579.
  • Lammering et al. 2004. Clin Cancer Res. 10(19):6732-43. PMID: 15475464.
  • Nishikawa et al. 2004. Brain Tumor Pathol. 21(2):53-6. PMID: 15700833.
  • Jungbluth et al. 2003. Proc Natl Acad Sci U S A. 100(2):639-44. PMID: 12515857.
  • Johns et al. 2002. Int J Cancer. 9...